Close Menu

NEW YORK – Tempest Therapeutics announced Thursday that the investigational new drug application for TPST-1495 has been accepted by the US Food and Drug Administration. The company will now initiate a Phase Ia/Ib clinical trial in solid tumors, with a focus on patients with microsatellite stable colorectal cancer.

TPST-1495 is a first-in-human investigational agent that inhibits prostaglandin receptors EP2 and EP4, which have been strongly implicated in colorectal cancer

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Sponsored by

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.